SCHEMBL2569262

SCHEMBL2569262

CC(F)(F)c1c(C(=O)O)noc1-c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.58
DUSP3 P51452 8/20 0.50
S1PR1 P21453 2/20 0.43
S1PR3 Q99500 1/20 0.43
ALDH1A1 P00352 3/20 0.41
IP6K1 Q92551 3/20 0.41
IP6K3 Q96PC2 3/20 0.41
IP6K2 Q9UHH9 3/20 0.41
TP53 P04637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PTGS1 P23219 1/20 0.41
TRPV1 Q8NER1 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALOX5 P09917 1/20 0.39
ALOX5AP P20292 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2570454 0.88 PTPN1 (0.61) PTPN1DUSP3S1PR1S1PR3ALDH1A1
SCHEMBL1225779 0.88 PTPN1 (0.61) PTPN1DUSP3S1PR1S1PR3ALDH1A1
SCHEMBL2568840 0.86 PTGS1 (0.53) PTPN1DUSP3S1PR1S1PR3ALDH1A1
SCHEMBL2562165 0.84 PTPN1 (0.54) PTPN1DUSP3S1PR1S1PR3ALDH1A1
SCHEMBL1225753 0.77 PTPN1 (0.51) PTPN1DUSP3S1PR1S1PR3ALDH1A1
SCHEMBL4076415 0.76 PTPN1 (0.67) PTPN1DUSP3ALDH1A1IP6K1IP6K3
SCHEMBL17079305 0.76 PTPN1 (0.67) PTPN1DUSP3ALDH1A1IP6K1IP6K3
SCHEMBL1806543 0.75 PTGS1 (0.55) PTPN1DUSP3S1PR1ALDH1A1IP6K1
SCHEMBL2565407 0.74 PTPN1 (0.46) PTPN1DUSP3S1PR1S1PR3ALDH1A1
SCHEMBL2567880 0.74 PTPN1 (1.00) PTPN1DUSP3ALDH1A1IP6K1IP6K3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354398-B2 Substituted isoxazole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-15 US disclosed
US-8354398-B2 Substituted isoxazole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-15 US disclosed
US-8354398-B2 Substituted isoxazole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-15 US disclosed
US-20110300165-A1 SUBSTITUTED ISOXAZOLE COMPOUNDS The Board of TRustees of the University of Illinoi University of Illinios (US) 2011-12-08 US disclosed
US-20110300165-A1 SUBSTITUTED ISOXAZOLE COMPOUNDS The Board of TRustees of the University of Illinoi University of Illinios (US) 2011-12-08 US disclosed
US-20110300165-A1 SUBSTITUTED ISOXAZOLE COMPOUNDS The Board of TRustees of the University of Illinoi University of Illinios (US) 2011-12-08 US disclosed
EP-2382212-A1 SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES Bristol-Myers Squibb Company (US) 2011-11-02 EP disclosed
WO-2010085581-A1 SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-29 WO disclosed
WO-2010085581-A1 SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110300165-A1 SUBSTITUTED ISOXAZOLE COMPOUNDS S1PR4, S1PR3, S1PR1 PTPN1 1421/4885DUSP3 3361/4885S1PR1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.